Login to Your Account

PharmaMar's Yondelis Phase III Trial Started In Ovarian Cancer

By Randall Osborne

Wednesday, April 6, 2005
Taking aim at relapsed ovarian cancer patients considered incurable, Madrid, Spain-based PharmaMar SA is starting a Phase III trial with Yondelis (trabectedin), a compound first isolated from marine tunicates. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription